Lapatinib ditosylate GlaxoSmithKline

IDrugs. 2003 Sep;6(9):886-93.

Abstract

Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / therapeutic use*
  • Furans / chemistry
  • Furans / therapeutic use*
  • Humans
  • Neoplasms / drug therapy
  • Quinazolines / chemistry
  • Quinazolines / therapeutic use*
  • Technology, Pharmaceutical / methods*

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Furans
  • N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
  • Quinazolines